Literature DB >> 27892799

Antiviral treatment of HBV positive pregnant women: an additional tool to reduce perinatal transmission.

Roberto Bruni1, Gloria Taliani2, Anna Rita Ciccaglione1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27892799      PMCID： PMC5189864          DOI： 10.1080/20477724.2016.1255375

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN： 2047-7724            Impact factor:   2.894


× No keyword cloud information.
  7 in total

1.  Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load.

Authors:  Calvin Q Pan; Zhongping Duan; Erhei Dai; Shuqin Zhang; Guorong Han; Yuming Wang; Huaihong Zhang; Huaibin Zou; Baoshen Zhu; Wenjing Zhao; Hongxiu Jiang
Journal:  N Engl J Med       Date:  2016-06-16       Impact factor: 91.245

2.  Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.

Authors:  Robert S Brown; Elizabeth C Verna; Marcus R Pereira; Hugh H Tilson; Christopher Aguilar; Cheng-Shiun Leu; Maria Buti; Elizabeth A Fagan
Journal:  J Hepatol       Date:  2012-07-02       Impact factor: 25.083

3.  Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.

Authors:  Leonardo Palombi; Maria F Pirillo; Emilia Marchei; Haswell Jere; Jean-Baptiste Sagno; Richard Luhanga; Marco Floridia; Mauro Andreotti; Clementina Maria Galluzzo; Simona Pichini; Ruben Mwenda; Sandro Mancinelli; Maria Cristina Marazzi; Stefano Vella; Giuseppe Liotta; Marina Giuliano
Journal:  J Antimicrob Chemother       Date:  2015-12-17       Impact factor: 5.790

4.  In Utero Tenofovir Exposure Is not Associated With Fetal Long Bone Growth.

Authors:  Jennifer Jao; Elaine J Abrams; Tamsin Phillips; Greg Petro; Allison Zerbe; Landon Myer
Journal:  Clin Infect Dis       Date:  2016-03-23       Impact factor: 9.079

5.  Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life.

Authors:  Mark Mirochnick; Taha Taha; Regis Kreitchmann; Karin Nielsen-Saines; Newton Kumwenda; Esau Joao; Jorge Pinto; Breno Santos; Teresa Parsons; Brian Kearney; Lynda Emel; Casey Herron; Paul Richardson; Sarah E Hudelson; Susan H Eshleman; Kathleen George; Mary G Fowler; Paul Sato; Lynne Mofenson
Journal:  J Acquir Immune Defic Syndr       Date:  2014-01-01       Impact factor: 3.731

6.  Requirements for global elimination of hepatitis B: a modelling study.

Authors:  Shevanthi Nayagam; Mark Thursz; Elisa Sicuri; Lesong Conteh; Stefan Wiktor; Daniel Low-Beer; Timothy B Hallett
Journal:  Lancet Infect Dis       Date:  2016-09-13       Impact factor: 71.421

7.  Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen.

Authors:  Gonzague Jourdain; Nicole Ngo-Giang-Huong; Tim R Cressey; Lei Hua; Linda Harrison; Camlin Tierney; Nicolas Salvadori; Luc Decker; Patrinee Traisathit; Wasna Sirirungsi; Woottichai Khamduang; Chureeratana Bowonwatanuwong; Thanyawee Puthanakit; George K Siberry; Diane Heather Watts; Trudy V Murphy; Jullapong Achalapong; Suchat Hongsiriwon; Virat Klinbuayaem; Satawat Thongsawat; Raymond T Chung; Stanislas Pol; Nantasak Chotivanich
Journal:  BMC Infect Dis       Date:  2016-08-09       Impact factor: 3.090
  7 in total
  1 in total

1.  The effectiveness of 20 μg hepatitis B vaccine used for the prevention of HBV vertical transmission.

Authors:  Guo Yonghao; Chen Yanping; Dou Qiaohua; Feng Daxing; Zhang Yanyang; Zhao Dongyang; Guo Wanshen
Journal:  Sci Rep       Date:  2022-07-11       Impact factor: 4.996
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.